Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GSK plc (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GSK has delivered slightly stronger year-to-date (YTD) performance at about 12% compared to JNJ's 11%.
- GSK offers a higher dividend yield of 3.3% versus JNJ's 2.4%, appealing to income-focused investors.
- JNJ commands a much larger market capitalization of $548 billion against GSK's $109 billion, underscoring its scale and stability.
- Both stocks exhibit low volatility with betas around 0.35 (a measure of market sensitivity), making them defensive plays in healthcare.
- GSK trades at a lower trailing price-to-earnings (P/E) ratio of 14.5 versus JNJ's 26.4, suggesting relative value.
- Recent momentum favors GSK on specialty medicine growth, while JNJ benefits from MedTech recovery.
Introduction
GSK plc (GSK) and Johnson & Johnson (JNJ) represent two pillars of the global healthcare sector, both offering exposure to pharmaceuticals amid rising demand for innovative treatments and vaccines. This comparison is particularly relevant for dividend-seeking investors and traders navigating volatile markets, as both deliver defensive qualities with low betas and steady cash flows. By examining recent performance, valuations, and strategic focuses, investors can assess relative strengths in a sector buoyed by aging populations and medical advancements. Understanding their market positioning aids decisions on stock rotation or portfolio allocation in healthcare.
GSK Overview and Recent Performance
GSK plc (GSK), a UK-based biopharma leader, specializes in specialty medicines (including HIV and oncology), vaccines, and general medicines. Shares have traded in the mid-$50s range amid recent market activity, reflecting year-to-date gains of nearly 12%. Positive sentiment stems from robust sales in specialty medicines and respiratory products, alongside pipeline progress in immunology. Recent weeks have highlighted strong full-year outlooks boosted by new launches, with upcoming earnings anticipated to underscore growth continuity. The stock's 52-week range spans $35 to $62, positioning it near highs, influenced by favorable analyst views despite occasional legal hurdles like licensing disputes.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), a U.S. healthcare conglomerate, operates through Innovative Medicine (pharmaceuticals) and MedTech (devices) segments. Its shares hover around $228, posting YTD returns of about 11%. Recent performance reflects MedTech segment improvements and strategic acquisitions expanding its cardiac portfolio, following solid Q1 results with revenue up and earnings beats. Sentiment has been supported by ongoing innovation in areas like pulsed field ablation trials. Trading within a broad 52-week range of $146 to $252, the stock maintains stability, buoyed by its dividend aristocrat status and analyst upgrades, though facing broader sector pressures.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—ranging from short-term 5-minute signals to 60-minute holds—using technical and fundamental analysis, with categories like Signal Agents, Virtual Agents, and Brokerage Agents for copy trading. Selected for current market conditions, they feature risk management tools and customizable settings, helping traders adapt to volatility. While specific win rates vary, the trending list highlights bots excelling in real-time opportunities. Investors can explore these to match their timeframe and risk tolerance, potentially enhancing portfolio performance through AI-driven insights.
Head-to-Head Comparison
GSK emphasizes pure-play biopharma with higher exposure to vaccines and specialty drugs, contrasting JNJ's diversification into MedTech for balanced revenue streams. Growth drivers differ: GSK's superior return on equity (ROE, 43%) and lower PEG ratio (0.50) signal efficient expansion, while JNJ leverages scale with $96 billion in trailing revenue. Recent momentum is comparable YTD, but GSK edges on valuation trade-offs like cheaper P/E. Risk profiles align with low betas, though JNJ's lower debt-to-equity (68%) adds resilience. Sector exposure favors JNJ in devices amid procedural growth, while GSK rides pharma tailwinds. Market sentiment remains constructive for both, with analysts projecting upside.
Tickeron AI Verdict
Tickeron's AI currently favors GSK over JNJ, based on trend consistency in specialty medicines, a more attractive trailing P/E and dividend yield, and near-term catalysts like earnings. While JNJ offers superior scale and MedTech stability, GSK's relative value and momentum position it probabilistically stronger in the near term for growth-oriented healthcare exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a StrongBuy and JNJ is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 2 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 2 green, 3 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 6 TA indicator(s) are bullish while JNJ’s TA Score has 6 bullish TA indicator(s).
- GSK’s TA Score: 6 bullish, 3 bearish.
- JNJ’s TA Score: 6 bullish, 3 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +2.95% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +3.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.
Reported Earning Dates
GSK is expected to report earnings on Jul 28, 2026.
JNJ is expected to report earnings on Jul 15, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | JNJ | GSK / JNJ | |
| Capitalization | 105B | 580B | 18% |
| EBITDA | 10.1B | 33.7B | 30% |
| Gain YTD | 10.022 | 17.682 | 57% |
| P/E Ratio | 13.97 | 27.91 | 50% |
| Revenue | 32.8B | 96.4B | 34% |
| Total Cash | 3.44B | 22.1B | 16% |
| Total Debt | 19.1B | 55B | 35% |
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 37 | 10 | |
SMR RATING 1..100 | 26 | 36 | |
PRICE GROWTH RATING 1..100 | 48 | 45 | |
P/E GROWTH RATING 1..100 | 83 | 18 | |
SEASONALITY SCORE 1..100 | 65 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (9) in the Pharmaceuticals Major industry is in the same range as JNJ (13). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is in the same range as GSK (37). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
GSK's SMR Rating (26) in the Pharmaceuticals Major industry is in the same range as JNJ (36). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as GSK (48). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
JNJ's P/E Growth Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (83). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | 1 day ago 29% |
| Stochastic ODDS (%) | 1 day ago 37% | 1 day ago 43% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 42% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 33% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 43% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 46% |
| Advances ODDS (%) | 1 day ago 61% | 4 days ago 44% |
| Declines ODDS (%) | 12 days ago 55% | 12 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 68% | N/A |
| Aroon ODDS (%) | 1 day ago 37% | 1 day ago 45% |
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.